EyePoint Pharmaceuticals: Key Contradictions in Phase 3 Trial Timelines and FDA Interactions

None



Rapid Enrollment in Phase 3 Trials:
- EyePoint Pharmaceuticals achieved rapid enrollment in its Phase 3 trials, surpassing 90% enrollment in the LUGANO trial and over 50% in the LUCIA trial.
- This was driven by strong physician and patient interest in DURAVYU, as well as the robust efficacy and safety profile demonstrated in previous trials.

DURAVYU's Clinical Potential in Wet AMD:
- DURAVYU's Phase 2 data showed that approximately two-thirds of patients remained rescue-free for six months, with nearly half remaining rescue-free for one year.
- The trial results and the differentiated mechanism of action, which targets both VEGF and PDGF receptors, have attracted attention and high enrollment rates.

Positive DME Trial Results:
- The VERONA trial in DME demonstrated compelling efficacy and durability, with DURAVYU's 2.7 milligram dose showing a 7.1-letter improvement in BCVA and a 76-micron reduction in OCT measurements.
- Outcomes in the trial were attributed to DURAVYU's immediate bioavailability and could position it as a potential paradigm-shifting treatment in DME.

Financial Health and Cash Position:
- EyePoint ended the first quarter with $318.2 million in cash and investments, affirming previous guidance that this cash will support operations into 2027.
- The financial health is attributed to disciplined financial management and the expectation that current cash levels will cover operations beyond pivotal trial data readouts.